OncLive TV

Dr. Pecora on How MACRA Needs Fine Tuning

August 12th 2016

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, talked about the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) and other aspects of healthcare reform.

Dr. Pecora on the Medicare Part B Drug Payment Model

August 12th 2016

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the Medicare Part B Drug Payment Model (OCM) and other aspects of healthcare reform.

Dr. Patnaik on Challenges With Sequencing Therapies in mCRPC

August 11th 2016

Akash Patnaik, MD, PhD, assistant professor of Medicine at the University of Chicago Medicine, discusses the challenges with sequencing available agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Dang on Neratinib in Patients With HER2-Positive Breast Cancer

August 11th 2016

Chau Dang, MD, medical oncologist, chief, West Harrison Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the potential of neratinib as a combination treatment for patients with HER2-positive breast cancer.

Dr. Filippo Pietrantonio on Using Nomogram for Patient Selection in CRC Trials

August 11th 2016

Dr. Susan O'Brien Compares Ibrutinib With Chemoimmunotherapy in Frontline CLL

August 11th 2016

Susan M. O'Brien, MD, associate director for Clinical Science for the Chao Family Comprehensive Cancer Center, medical director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, UC Irvine Health, discusses how ibrutinib (Imbruvica) compares with chemoimmunotherapy as a frontline treatment for patients with chronic lymphocytic leukemia.

Dr. Reinhard Dummer on Toxicities with Binimetinib in Metastatic Melanoma

August 11th 2016

Dr. Michael L. Blute on Partial Nephrectomy Rates in RCC

August 10th 2016

Dr. Nussenbaum on Organ Preservation for Patients With Larynx Cancer

August 10th 2016

Brian Nussenbaum, MD, Christy J. and Richard S. Hawes III Professor, Otolaryngology-Head and Neck Surgery, director, Head and Neck Surgical Oncology, vice chair of Clinical Affairs, patient safety officer, Washington University School of Medicine in St. Louis, discusses which patients with larynx cancer are eligible for organ preservation surgery.

Dr. Dixon on Prevalence and Risk Factors of Male Breast Cancer

August 10th 2016

J. Michael Dixon, MD, professor of Surgery, consultant surgeon, and clinical director of the Breakthrough Breast Cancer Research Unit at the University of Edinburgh in Scotland, discusses the prevalence of and risk factors for breast cancer in males.

Dr. Frankie Ann Holmes on Duel Anti-HER2-Directed Therapy in Breast Cancer

August 10th 2016

Dr. Leslie Randall Discusses Evidence Supporting BRCA Testing in Ovarian Cancer

August 10th 2016

Leslie M. Randall, MD, associate professor of Gynecology/ Oncology, University of California Irvine, discusses evidence supporting the use of BRCA testing for patients with ovarian cancer.

Dr. Jonathan Trent on Pembrolizumab in Advanced Sarcomas

August 9th 2016

Dr. Arteaga on Ongoing Trials in Metastatic Breast Cancer

August 9th 2016

Carlos L. Arteaga, MD, associate director for Clinical Research, director, Center for Cancer Targeted Therapies, Vanderbilt-Ingram Cancer Center, discusses some of the ongoing trials exploring treatments for patients with metastatic breast cancer.

Dr. John Byrd on Ibrutinib in CLL

August 9th 2016

Dr. West on Advancements for Patients With T790M-Mutant NSCLC

August 8th 2016

Howard L. (Jack) West, MD, medical oncologist, director, Thoracic Oncology Program, Swedish Cancer Institute, discusses recent advancements for patients with T790M-mutant non–small cell lung cancer.

Dr. Lehman on 3D Mammography in Screening for Breast Cancer

August 8th 2016

Constance D. Lehman, MD, PhD, professor of radiology and chief of Breast Imaging in the Department of Radiology at Massachusetts General Hospital, discusses how 3D mammography has been an efficient and beneficial screening tool in the field of breast cancer.

Dr. Harold J. Burstein on CDK4/CDK6 Inhibitor Abemaciclib in Breast Cancer

August 7th 2016

​Harold J. Burstein, MD, PhD, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute discusses the results of MONARCH1, which looked at abemaciclib as monotherapy in patients with ER-positive breast cancer, after chemotherapy for advanced disease.

Dr. Neal Shore on Increasing Healthcare Costs and Metastasis Risk in Prostate Cancer

August 7th 2016

​Neal Shore, MD, medical director of the Carolina Urologic Research Institute, discusses a retrospective study investigating the relationship between treatment costs and the timing of diagnosis of metastases in prostate cancer.

Dr. Ferris on FDA Approval of Pembrolizumab in Head and Neck Cancer

August 6th 2016

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the impact of the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with head and neck cancer.